Pharmacokinetics of Carboplatin in Cancer Patients
Author Information
Author(s): P.O.M. Mulder, E.G.E. de Vries, D.R.A. Uges, A.H.J. Scaf, D.Th. Sleijfer, N.H. Mulder
Primary Institution: University Hospital, Groningen, The Netherlands
Hypothesis
The study investigates the pharmacokinetics of carboplatin in patients with disseminated ovarian and testicular cancer.
Conclusion
Carboplatin can be safely administered with bone marrow reinfusion performed 48 hours after the last dose, as the drug is unlikely to be cytotoxic at that time.
Supporting Evidence
- Carboplatin was given as part of an ablative combination regimen followed by autologous bone marrow transplantation.
- Fifty-three percent of the administered carboplatin was excreted in the urine in the first 6 hours.
- Plasma ultrafiltrated Pt and carboplatin decreased to undetectable levels within 48 hours.
Takeaway
This study looked at how a cancer drug called carboplatin behaves in the body, showing that it can be given safely before a bone marrow transplant.
Methodology
Five patients received carboplatin intravenously over three consecutive days, and blood and urine samples were analyzed for platinum levels.
Limitations
The study had a small sample size of only five patients.
Participant Demographics
Patients included two with end-stage ovarian cancer and three with relapsed testicular cancer, all having received prior chemotherapy.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website